Home > Insider Trading > Filing (0000899243-19-008407)

Filing Details

Accession Number:: 0000899243-19-008407
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-03-19 19:00:37
Reporting Period:: 2019-03-15

Accepted Time:: 2019-03-19 19:00:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1351288	Gw Pharmaceuticals Plc	GWPH	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1754129	D. Justin Gover	Sovereign House, Vision Park, Histon Cambridge X0 CB24 9BZ	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2019-03-15	47,851	$0.00	564,960	No	4	M	Direct
Ordinary Shares	Disposition	2019-03-15	19	$13.88	564,941	No	4	D	Direct
Ordinary Shares	Disposition	2019-03-15	23,400	$14.01	541,541	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	D	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Options	Disposition	2019-03-15	17,517	$0.00	17,517	$0.00
Ordinary Shares	Stock Options	Disposition	2019-03-15	30,334	$0.00	30,334	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2018-01-06	2019-03-15	No	4	M	Direct
60,668			No	4	M	Direct

Footnotes

Exercise of stock options. Following the exercise, 47,832 of these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.
Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of March 15, 2018.
Includes (a) 67,320 ordinary shares underlying restricted stock units previously reported as stock options on Table II of the reporting person's Form 3 filed on October 1, 2018, of which 22,440 shares will vest automatically on February 26, 2020, 2021 and 2022, respectively and (b) 68,016 ordinary shares underlying restricted stock units previously reported as stock options on Table II of the reporting person's Form 4 filed on March 5, 2019, of which 17,004 shares will automatically vest on March 1, 2020, 2021, 2022 and 2023, respectively.
The price reported in Column 4 is price per ordinary share converted from price per ADS.
The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2018.
The price reported in Column 4 is a weighted average price per ordinary share ($168.09 per ADS). These shares were sold in multiple transactions at prices ranging from $167.59 per ADS (or $13.97 per ordinary share) to $168.54 per ADS (or $14.05 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The reported transaction related to exercise of stock options to purchase 30,334 shares which vested on February 15, 2018. The remaining stock options vest equally on February 15, 2019 and 2020, and will expire 13 months after vesting date.